Other recent partnerships in the molecular glue degrader category include Takeda's recent $1 billion-plus link-up with Degron Therapeutics, a $1.46 billion deal between Novo Nordisk and Neomorph ...

Novartis has accelerated its efforts to develop protein degrader therapies by licensing a prostate cancer candidate from Arvinas on the brink of starting phase 3 trials in a deal worth over $1 ...

Matthew R. Levengood; Christopher M. Carosino; Xinqun Zhang; Sasha Lucas; David J. Ortiz; Lori Westendorf; Alice P. Chin; Arlan D. Martin; Abbie Wong; Shawna M ...

Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan, Ann Arbor 48109, United States ...

developing ligands to bind currently undruggable targets and using computation for degrader design/optimization. Increasingly, pharmaceutical companies are investing in biotech acquisitions ...